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ABSTRACT
The LILRs are a family of receptors that regulate the activities of myelomonocytic 
cells. We found that specific allelic variants of two related members of the LILR family, 
LILRB3 and LILRA6, interact with a ligand exposed on necrotic glandular epithelial 
cells. The extracellular domains of LILRB3 and LILRA6 are very similar and their 
genes are highly polymorphic. A commonly occurring allele, LILRB3*12, displayed 
particularly strong binding of these necrotic cells and further screening of the products 
of LILRB3 alleles identified motifs that correlated with binding. Immunoprecipitation 
of the ligand from epithelial cell lysates using recombinant LILRB3*12, identified 
cytokeratins 8, 18 and 19. Purified proteins obtained from epithelial cell lysates, 
using anti-cytokeratin 8 antibodies, were able to activate LILRB3*12 reporter cells. 
Knock-down of cytokeratin 8 in epithelial cells abrogated expression of the LILRB3 
ligand, while staining with recombinant LILRB3*12 showed co-localisation with 
cytokeratin 8 and 18 in permeabilised breast cancer cells. Necrosis is a common 
feature of tumours. The finding of a necrosis-associated ligand for these two receptors 
raises the possibility of a novel interaction that alters immune responses within the 
tumour microenvironment. Since LILRB3 and LILRA6 genes are highly polymorphic 
the interaction may influence an individual’s immune response to tumours.
INTRODUCTION
Necrotic cell death commonly occurs in tumour 
cells where it may be a consequence of impaired apoptosis 
(programmed cell death). Necrotic cells release large 
amounts of intracellular molecules exhibiting Damage-
Associated Molecular Patterns (DAMPs) that alter the 
immune response upon recognition by professional 
antigen presenting cells (APC) such as macrophages, 
monocytes and dendritic cells (DC).
The leukocyte Ig-like receptors (LILR), encoded 
in the leukocyte receptor complex, are a family of 
innate immune receptors that regulate the behaviour of 
myelomonocytic cells [1, 2]. The LILR gene complex 
encodes multiple receptors with either inhibitory functions, 
determined by ITIM motifs in their cytoplasmic domains, 
or activating functions, due to their association with 
ITAM-bearing adaptor molecules. The competing activities 
of activating and inhibitory members of the LILR family 
are thought to finely balance the functions of innate immune 
cells and dictate their response to infected, stressed, 
transformed and normal cells. Members of the LILR 
family are involved in the control of human DC maturation, 
cytokine production and the expression of co-stimulatory 
molecules that direct adaptive immunity [3-7].
LILR are divided into two groups based on their 
ability to bind MHC Class I molecules [8]. Much is 
already known about the ligands of group 1 LILR, which 
are MHC class I [9], but far less about the ligands of 
group 2. With the exception of LILRA4, which binds to 
CD317 and is reported to regulate toll-like receptor (TLR) 
-7 and -9 responses in plasmacytoid dendritic cells [10], 
the remainder of the group 2 LILR remain unclassified, as 
orphan receptors.
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The inhibitory LILRB3 and activating LILRA6 are 
examples of group 2 LILR that currently have no identified 
ligand. In common with most other LILR they are expressed 
by myelomonocytic leukocytes, but in contrast to others, 
they are the only ‘paired’ receptors in the LILR family, since 
they have almost identical extracellular domains but differ 
in their signalling activities [11]. A particularly interesting 
feature of the LILRB3 and LILRA6 genes is the high level 
of non-synonymous variation. The variable nucleotides 
exhibit similar distributions in both genes [12].
In this study we provide evidence that LILRB3 and 
LILRA6 interact with a novel ligand exposed on necrotic 
epithelial cells. We explore this interaction in the context 
of LILRB3 and LILRA6 allelic variation and demonstrate 
recognition of a ligand associated with cytokeratin 8.
RESULTS
LILRB3 binds to a ligand expressed by 
glandular epithelial cells
To screen for LILRB3 ligands on the surface of 
tumour cells, we constructed 2B4 reporter cells that 
expressed the extracellular domains of a commonly 
occurring allelic variant of LILRB3 [allele LILRB3*12, 
(12)], or LILRB1 fused to the human CD3ζ cytoplasmic 
domain. Signalling through these hybrid receptors results 
in the expression of GFP, which can be detected by flow 
cytometry. LILRB3 reporter cells were co-seeded and 
cultured with a wide range of human tumour cell lines 
including those derived from B cells and epithelial cells. 
Figure 1A shows results from a selection of these lines. 
The EBV positive and negative Burkitt’s lymphoma B 
cell lines Daudi and BJAB, the embryonic kidney cell line 
HEK293T and an HLA-G transfected EBV transformed B 
cell line 721.221 did not induce the expression of GFP in 
the LILRB3 reporter 2B4 cells. In contrast, the epithelial 
cell line MCF-7 (breast glandular), T47D (breast ductal) 
and HCT-116 (colon) induced the expression of GFP, 
suggesting that a ligand for LILRB3 is present on these 
cells (Figure 1A). To demonstrate that this effect was 
specific to LILRB3, 2B4 cells expressing LILRB1 (which 
binds to MHC class I molecules) fused to the human CD3ζ 
cytoplasmic domain, were also co-cultured with the panel 
of cells. The level of GFP expression in the LILRB1 2B4 
cells followed the known level of expression of MHC 
class I molecules on each of the target cell types. Levels 
of MHC class I molecules were determined by staining 
with the pan HLA class I mAb W6/32 (data not shown). 
The epithelial cell lines did not activate the LILRB1 2B4 
cells to a high level (Figure 1A). Untransfected 2B4 cells 
were not activated by any of the cell lines tested (data not 
shown).
Flow cytometry of cells stained with recombinant, 
soluble LILRB3 (allele LILRB3*12) fused to the Fc 
portion of human IgG1 bound to glandular epithelial 
tumour cells (Figure 1B), confirming the pattern of 2B4 
activation (Figure 1A). Co-staining with the DAPI nuclear 
stain indicated LILRB3-Fc binding to dead epithelial 
tumour cells (Figure 1C), suggesting that a LILRB3 
ligand is exposed on these cells following necrosis. The 
pattern of control LILRB1-Fc staining was consistent 
with LILRB1-2B4 reporter cell activation (Figure 1B), 
and did not display any increase in binding to dead cells 
(Figure 1C).
Non-tumour human breast epithelial cells were 
then assessed using the 2B4 reporter cells. Epithelial cells 
cultured from four subjects tested induced expression 
of GFP by the LILRB3 reporter (Supplementary Figure 
S1), suggesting that expression of the ligand of LILRB3 
is not specific to tumour cells and may also be expressed 
on cells of glandular epithelial origin, whether normal or 
transformed.
The ligand of LILRB3 is exposed on necrotic 
glandular epithelial cells
The binding of LILRB3 to dead epithelial 
tumour cells was assessed further by staining cells with 
recombinant Fc fusion molecules following treatment with 
H2O2 or NaN3 (to induce necrosis), staurosporine (STS, to 
induce apoptosis) or subjected to mechanical damage by 
repeated trituration. Cell death was confirmed by Annexin 
V and DAPI staining (Supplementary Figure S2), while 
necrosis and apoptosis were determined by morphological 
features such as cell shrinkage (apoptosis), cellular 
swelling (necrosis) and formation of apoptotic bodies 
(Supplementary Figure S3).
LILRB3-Fc (allele LILRB3*12) was not observed to 
bind viable cells (adherent cells were stained in situ prior 
to harvesting to avoid cell damage during cell dissociation) 
but bound strongly to MCF-7, T47D and HCT-116 cells 
following H2O2 induced necrosis and mechanically 
induced lysis (Figure 2A). There was moderate binding 
to cells treated with NaN3. Following STS treatment, 
only a small proportion of apoptotic cells were bound 
by LILRB3-Fc (Figure 2A). LILRB3 was not observed 
to bind to Daudi or 293T cells either before or following 
treatments (data not shown). Binding of LILRB1-Fc was 
not affected by the cell treatments (data not shown).
To confirm LILRB3 recognition of a ligand exposed 
on necrotic cells, 2B4 reporter cells were co-cultured with 
target cells previously treated with H2O2 or NaN3 and 
following H2O mediated lysis (Figure 2B). The LILRB3 
reporter (allele LILRB3*12) was activated by all three 
epithelial cell lines following H2O and H2O2 treatments but 
not by viable cells. The LILRB3 reporter also responded 
to MCF-7 and HCT-116 (but not T47D) cells previously 
treated with NaN3. Both Daudi (Figure 2B) and 293T (data 
not shown) failed to activate the reporter irrespective of 
treatments. LILRB1 reporter responses were largely 
unaffected by the target cell treatments (Figure 2B). The 
2B4 system is highly sensitive to STS induced apoptosis 
and was not compatible with STS treated cells.
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Polymorphism of LILRB3 influences binding to 
the glandular epithelial cell ligand
LILRB3 and LILRA6 genes display substantial 
polymorphic variation that results in amino acid 
substitutions [12]. Analysis of LILRB3 and LILRA6 cDNA 
sequences provided statistically significant evidence that 
variation at residues 36, 46, 97, 164, 182, 265, 318, 327, 
377 and 386 of the mature protein has been subject to 
positive selection (Supplementary Table S1, analysis was 
performed using sequences provided in Supplementary 
Table S2 Residues 36 and 97 align to positions known 
to make up the MHC class I molecule- binding sites of 
the group 1 LILR proteins, along with polymorphic sites 
38, 67, 99 and 126 [8, 13]. To determine whether these 
and any other amino acids are similarly involved in the 
binding of LILRB3 and LILRA6 to glandular epithelial 
cells, constructs of selected LILRB3 and LILRA6 variants 
were prepared.
An initial screen of the LILR-Fc fusion proteins 
for their binding to mechanically damaged epithelial cell 
lines identified two products from the alleles LILRB3*01 
and LILRB3*12 that displayed very low, and very high, 
binding respectively (Figures 3A&3B), while products 
from alleles LILRB3*09 and LILRA6*05 exhibited 
Figure 1: LILRB3 interacts with a ligand on glandular epithelial cells. A. Flow cytometry dot plots showing that 2B4 reporter 
cells expressing hybrid proteins of LILRB1 and commonly occurring allelic variant of LILRB3 (allele LILRB3*12) and the human CD3ζ 
cytoplasmic domain produce GFP when activated through the hybrid receptor. Reporter cells were co-incubated with the glandular epithelial 
cell lines MCF-7, T47D and HCT-116, the non-epithelial cell line HEK293T (labelled 293T on figure), HLA-G transfected 721.221 
(labelled 221/HLA-G) and B cell lines Daudi and BJAB. The percentage of GFP positive reporter cells is indicated. The results provided are 
representative of five experiments. B. Flow cytometry histogram plots displaying staining of cells with a LILRB1-Fc or LILRB3-Fc (allele 
LILRB3*12) fusion protein (no fill) or a non-hybrid Fc negative control (grey fill). Representative results of five experiments are shown. 
C. LILRB3-Fc (allele LILRB3*12), but not LILRB1-Fc, binds primarily to dead epithelial cells. Cell death was determined by the uptake of 
the nuclear stain DAPI. Dead cells intrinsically comprised a proportion of the cells. Representative results of four experiments are shown.
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intermediate binding. Similar results were found in 2B4 
reporter assays (Figure 4A).
Sequences were reciprocally exchanged between 
the low binding LILRB3*01 and high binding LILRB3*12 
followed by the expression of the hybrid LILRB3 molecules 
as LILR-Fc fusion proteins. They were used to stain MCF-
7 cells. These experiments identified three broad regions in 
Ig domains D1, D3 and D4 that appeared to cooperate in 
binding (Supplementary Figure S4). Amino acids associated 
with ligand binding included Q36, L46 and Q67 in Ig 
domain D1, R265 and Y267 in Ig domain D2, and M318, 
R325, G326, Y327 and R377 in Ig domain D4.
To refine the LILRB3 ligand binding sites further, 
these data were used to design a higher resolution screen 
of the amino acids identified in the hybrid LILRB3. This 
panel of chimeric LILRB3-Fc fusion molecules was 
used to determine which of the amino acids in each of 
the broad regions identified in Supplementary Figure S4 
were most important for binding (Figures 3C&3D). The 
LILRB3 amino acids most closely associated with binding 
to the ligand were: Q67, which was enhanced by W46 
(D1 domain); R265 (D3 domain); R325/G326 and Y327 
(encoded by linked single nucleotide polymorphisms 
[SNPs]) when in the presence of R377 (D4 domain) 
(Figures 3A-D).
2B4 reporter cells, transfected with the naturally 
occurring LILRB3 and LILRA6 variants alongside 
chimeric LILRB3 molecules confirmed that binding is 
influenced by more than one linear motif and supported 
the earlier findings for binding sites in D1 and D3 when 
LILR-Fc fusion proteins were used to stain MCF-7 cells 
(Figures 4A&4B). There was, however, a discrepancy 
regarding the RGYR motif in the D4 domain. With soluble 
LILRB3-Fc fusion proteins, this motif, when incorporated 
into the non-ligand binding LILRB3*01 allele, showed 
moderate binding to the LILRB3 epithelial ligand (Figures 
3C&3D). When this chimeric LILRB3 was expressed as a 
receptor on 2B4 cells, however, the motif failed to induce 
a response unless in the presence of either of the D1 or D3 
binding-associated motifs (Figure 4B).
Interaction with the glandular epithelial cell 
ligand of LILRB3 involves more than one Ig 
domain
Data from binding and reporter assays were used to 
position the identified ligand- binding sites on molecular 
models of LILRB3 based on the structures of related 
molecules. Sites within the D1 domain of LILRB3 
(residues 46 and 67) were in similar positions on structures 
Figure 2: LILRB3 recognises an epitope exposed on necrotic glandular epithelial cell lines. A. Staining of treated cells with 
LILRB3-Fc (allele LILRB3*12, no fill) or Fc negative control (grey fill). Cells were treated to induce lysis (H2O or by mechanical damage), 
necrosis (H2O2 or NaN3) or apoptosis (STS). Viable target cells underwent primary staining whilst adhered to culture plate. Representative 
results of 4 experiments are shown. B. 2B4 reporter cells were incubated with target cell lines previously treated with either H2O (to induce 
osmotic lysis), H2O2 or NaN3 (both necrotic agents). Viable adherent cells in lane 1 were washed to remove any dead cells prior to the 
addition of reporter cells. The LILRB3 2B4 reporter cells expressed the extracellular region of allele LILRB3*12. Results are from four 
independent experiments, each treatment was performed in duplicate. Results from an additional five independent experiments where 
MCF-7 cells were assessed alone are also included. Bars indicate mean values.
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based on LILR templates (Supplementary Figure S5). 
The placement of residue 46 in these models differed 
considerably from that of the structure based on the more 
distantly related NKp46 (structure 1p6f:A). The predicted 
structures of the D3 and D4 Ig domains of LILRB3 were 
produced from template alignments featuring comparable 
regions within LILRB1, LILRB2, LILRB4 and the 
more distantly related KIR molecules. Sites identified as 
interacting with the glandular epithelial ligand within D3 
[265(R)] and D4 [325-327 (RGY) and 377(R)] occurred 
in similar positions in all 4 models (Supplementary Figure 
S6). All models are consistent with 325-327 and 377 being 
in close proximity on the surface of LILRB3, although 
separated by ~50 amino acids.
A four Ig domain structure of LILRB3 was 
constructed from the Raptor X generated models of 
D1-D2 and D3-D4 (Figure 5), both of which scored 
well in terms of energy and stereochemical properties 
Figure 3: LILRB3-Fc and LILRA6-Fc polymorphic variants differentially bind to mechanically damaged glandular 
epithelial tumour cells lines. A. The non-epithelial HEK-293T and the epithelial tumour cell T47D were stained with naturally occurring 
variants of LILRB3-Fc and LILRA6-Fc. Representative histograms are shown; shaded peaks indicate staining with the Fc negative control 
protein. Cells were stained with the anti-human cytokeratin 8-specific monoclonal antibody 1E8 as a positive control. B. The overall mean 
average and standard deviation resulting from four replicate experiments where each treatment was performed in duplicate are provided. 
Individual LILRB3-Fc and LILRA6-Fc mean fluorescence intensity (MFI) values were normalised for background by subtracting the Fc 
negative control MFI values. Representative staining with chimeric Fc molecules that combined motifs from high and low ligand binding 
LILR variants are provided in C. while the overall mean average and standard deviation resulting from four replicate experiments are 
shown in panel D.
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(Supplementary Tables S3 and S4), with 95.5% and 94.4% 
of residues occurring within their most favoured positions 
respectively. The sites identified as interacting with the 
glandular epithelial ligand were predicted to occur on one 
face of the LILR molecule (Figure 5).
LILRB3 interacts with a cytokeratin - associated 
ligand
LILRB3*12 displayed the strongest binding to 
necrotic glandular epithelial cells. Products of this 
allele were used subsequently to identify the ligand. 
The LILRB3*12-Fc fusion protein was used to 
immunoprecipitate the putative LILRB3 ligand from 
lysates of T47D, MCF7 and HCT116 epithelial cells, using 
the non-epithelial B cell lines Daudi and BJAB as controls 
(Figure 6A). On SDS-PAGE gels, several reproducible, 
immunoprecipitated bands were identified in samples 
from the T47D, MCF7 and HCT116 epithelial cell lines 
that had also activated the LILRB3*12 2B4 reporter cells 
and had stained with LILRB3*12-Fc. In cells that neither 
activated the LILRB3*12 2B4 reporter cells nor stained 
with LILRB3*12-Fc, only low levels of background bands 
were seen.
Following analysis of the major bands by mass 
spectrometry (Figure 6B), five main proteins were 
identified. Three of these were cytokeratins 8, 18 and 
19, all of which are cytoskeletal intermediate filament 
proteins associated with glandular, ductal epithelial cells. 
The remaining proteins were the cytoskeletal component 
β-actin, which was isolated solely from epithelial cell 
lysates, and farnesyl diphosphate synthase (FDPS), an 
enzyme that may be involved in the metabolism of the 
human Vγ9Vδ2 T cell phosphoantigen, isopentenyl 
pyrophosphate [14]. FDPS was isolated from both 
epithelial and non-epithelial cell lysates alike. LILRB1-Fc 
also immunoprecipitated weak protein bands containing 
cytokeratins 8, 18 and 19 from MCF-7 cell lysates, and 
β-actin from both MCF-7 and Daudi cell lysates. Despite 
the apparent ‘stickiness’ of these intracellular cytoskeletal 
elements, the strong interaction of LILRB3*12 with the 
glandular ductal epithelial cytokeratins was investigated 
further. FDPS was ruled out as a potential ligand of 
LILRB3 as its expression could not be detected by flow 
cytometry (data not shown).
To confirm that LILRB3*12 binds to a complex 
of proteins involving cytokeratin 8 and that this binding 
was responsible for activating the LILRB3*12 2B4 cells, 
microsphere beads coated with the anti-human cytokeratin 
8 specific monoclonal antibody 1E8, or an isotype control, 
were incubated with membrane-enriched lysates from 
MCF7 or Daudi B cells prior to co-incubation with 2B4 
reporter cells expressing either LILRB3*12 or LILRB1, 
or with parental 2B4 cells. Ligands captured from the 
Figure 4: LILRB3 and -A6 polymorphisms influence cellular recognition of mechanically damaged breast cancer 
cells. Parental 2B4 reporter cells (2B4), and 2B4 cells transfected with the naturally occurring LILRB3 and LILRA6 variants A. and 
chimeric LILRB3/A6 sequences B. were used in co-culture with epithelial MCF-7 (striped bars) and non-epithelial HEK-293T (white bars) 
target cells. Mean and standard deviation values from 6 replicate experiments are shown. LILRB3/A6 molecules were cross-linked with a 
monoclonal antibody specific for the HA tag introduced into the N-terminus of the LILR during construction.
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MCF-7 lysate by 1E8, but not the isotype control, activated 
the LILRB3*12 - expressing 2B4 cells to produce GFP 
(Figure 6C); a similar percentage of LILRB3*12 2B4 cells 
were activated by a cross-linking anti-LILRB3 antibody. 
The parental 2B4 cells and the LILRB1 expressing 2B4 
cells were not activated by 1E8 ligands captured from 
either the MCF-7 or the Daudi cells. An anti-LILRB3 
antibody also failed to activate these cells.
These results are consistent with the finding that 
proteins affinity purified from epithelial cells along with 
cytokeratin 8 associate with LILRB3*12.
The LILRB3 ligand requires expression of the 
cytokeratin 8 gene
To further clarify the link between the expression 
of cytokeratin 8 and the expression of the ligand for 
LILRB3*12, shRNA constructs were used to stably silence 
the expression of cytokeratin 8 in MCF-7 epithelial cells. 
Using confocal microscopy, the intracellular levels of 
the 1E8 cytokeratin 8 epitope and LILRB3*12-Fc ligand 
were compared in MCF-7 cytokeratin 8 knock-down 
cells (MCF-7 CK8 KD) and MCF-7 cells that had been 
transduced with a non gene-specific shRNA construct 
(Figure 7). Compared with the control cells, which 
showed normal 1E8 and LILRB3*12-Fc binding (with 
clear co-localisation), MCF-7 CK8 KD cells expressed 
only background levels of the 1E8 cytokeratin 8 epitope 
and binding of LILRB3*12-Fc. The expression level of 
cytokeratin 18, as determined by the binding of DA-7, 
was also greatly reduced in MCF-7 CK8 KD cells (Figure 
7), demonstrating that cytokeratin 18 requires cytokeratin 
8 for stable expression [15]. Expression of cytokeratin 
19, the other binding partner of cytokeratin 8, was also 
Figure 5: Predicted locations of LILRB3 and LILRA6 polymorphisms that alter binding to necrotic glandular 
epithelial cells, and sites under strong evolutionary selection pressure. Molecular model of LILRB3 based on the structure 
of related LILR proteins. Ig domains are shaded in different colours with D1 at the bottom of the figure and D4 at the top. The labelled 
polymorphic residues are coloured to indicate their influence on ligand binding and selection pressure, as follows: Red= Polymorphic 
amino acids implicated in ligand binding that have undergone significant positive selection pressure; Purple= Putative ligand binding amino 
acids that are not under significant positive selection; Yellow=Amino acids that are undergoing positive selection, but do not appear to 
influence ligand binding; Blue=Amino acids undergoing negative selection. Amino acid 326 (coloured purple) is under significant negative 
selection and also implicated in binding.
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greatly reduced following the silencing of cytokeratin 8 
expression (data not shown).
Analysis of the mean fluorescence intensity of the 
1E8 epitope, the LILRB3*12-binding ligand and MHC 
class I on mechanically damaged MCF-7 and MCF-7 CK8 
KD cells showed that the expression of the LILRB3*12 
ligand, but not MHC class I, was significantly different 
between the MCF-7 and MCF-7 CK8 KD cells (Figure 
8A&8B). LILRB3 binding was assessed in this set of 
experiments using the LILRB3*12-Fc fusion protein.
Finally, necrotic MCF-7 CK8 KD cells previously 
treated with H2O2 were used with control MCF-7 and 
HEK293T non-epithelial cells in a co-culture assay with 
LILRB3*12, LILRB1 and non-LILR expressing parental 
2B4 reporter cells. None of the cell lines activated the 
parental 2B4 cells or the LILRB1 expressing cells. The 
LILRB3*12-expressing 2B4 cells were strongly activated 
by MCF-7 cells whilst the MCF-7 CK8 KD cells activated 
a low percentage of LILRB3*12 2B4 cells (Figure 8C). 
Similar results were obtained using mechanically damaged 
target cells and targets treated with NaN3 (data not 
shown). The recognition of MCF-7 cells by 2B4 reporter 
cells expressing LILRB3*09 and LILRA6*05 was also 
greatly reduced following the silencing of cytokeratin 
8 expression (Supplementary Figure S7). These shRNA 
knock-down experiments confirm that the expression 
of the LILRB3 ligand is dependent upon the expression 
of the cytokeratin 8 gene. This series of experiments 
Figure 6: The LILRB3 ligand co-purifies with cytokeratin 8 from the lysates of glandular epithelial cell lines. 
A. Coomassie blue stained SDS-PAGE gel of proteins immunoprecipitated by LILRB3*12-Fc from membrane-rich lysates of the epithelial 
cell lines MCF-7, T47D, and HCT116 compared with the non-epithelial cell lines BJAB and Daudi. The high molecular weight molecules 
(>64 kDa) in lanes 2-7 are LILR-Fc proteins. The Fc negative control protein in lane 1 has an apparent molecular weight of ~40kDa. 
B. A repeat Coomassie stained SDS-PAGE gel of proteins immunopreciptated by LILRB3*12-Fc from Daudi and MCF-7 cells. Bands were 
excised from the gel and were identified by mass spectrometry as cytokeratins (CK) 8, 18 and 19, β-actin and farnesyl diphosphate synthase 
(FDPS). C. Isolation of ligand of LILRB3*12 from cell lysates with the anti-human cytokeratin 8 specific mAb 1E8: Ligands captured from 
MCF-7 lysates (but not from Daudi B cells) on 1E8-coated microsphere beads were cultured with 2B4 reporter cells. Beads coated with 
isotype control antibody (iso) prior to incubation with lysates were used as a negative control. Beads coated in an anti-LILRB3 antibody 
were used as a positive control. The results shown are from 4 replicate experiments. Bars indicate mean values. Statistical significance was 
assessed using a two-tailed Mann Whitney test (**p<0.001).
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are all consistent with the assertion that certain allelic 
variants of LILRB3/A6 interact with a ligand, or ligands, 
associated with the expression of cytokeratin 8 by 
glandular epithelial cells.
DISCUSSION
We provide evidence that certain allelic variants 
of LILRB3 and LILRA6 recognise a ligand from 
necrotic glandular epithelial cells that is associated with 
cytokeratin 8 and is displayed on the cell-surface. The 
precise identity of the ligand remains to be determined. 
Cytokeratins are conventionally known as intracellular 
cytoskeletal molecules that form intermediate filaments 
(IF) in epithelial cells. Cytokeratin 8 forms heterodimers 
with cytokeratin 18 or 19 which then heteropolymerise to 
form intermediate filaments. These in turn interact with a 
wide range of other intracellular proteins, some of which 
may co-purify with cytokeratin 8. We showed that knock-
down of cytokeratin 8 ablated the binding of LILRB3*12 
to epithelial cells. However, intermediate filament 
polymerisation, and association with other proteins is 
dependent on the presence of cytokeratin 8. Therefore, 
the loss of the ligand on cytokeratin 8 knock-down cells 
could be due either to the ablation of direct binding to the 
cytokeratin itself, or indirectly due to the loss of a protein 
associated with cytokeratin 8. For this reason, we cannot 
unequivocally identify cytokeratin 8 as the ligand.
Given the intracellular location of cytokeratin 8 
our findings were unexpected. There are several reports 
of cytokeratin epitopes being present on the surface of 
epithelial tumours and cell lines [16-23]. However, we 
found little evidence for the presence of LILRB3 and 
LILRA6 ligand on viable cells. An explanation might 
be that normal cultures generally contain a proportion 
of necrotic cells, which are responsible for exposure of 
cytokeratin. Another possibility concerns sticking of 
cell debris, containing cytokeratin, to the surface of live 
cells. Some epithelial tumour cells release measurable 
levels of cytokeratin into plasma after they die by either 
necrosis or apoptosis. Levels of cytokeratin in plasma 
have been proposed, therefore, as a biomarker to predict 
and monitor responses to chemotherapy [24]. LILRB3 
2B4 reporter cells did not respond to soluble cytokeratin 
released from necrotic cells in tissue culture medium 
(data not shown). Furthermore, there was no evidence 
that etoposide-induced apoptosis, in contrast to necrosis, 
induces the exposure of the LILRB3 ligand on any cell 
line tested (Figure 2A). This difference may be explained 
partially by the cleavage and reorganisation of cytokeratin 
Figure 7: LILRB3-Fc binding of MCF-7 cells following shRNA silencing of the expression of cytokeratin 8 as assessed 
by confocal microscopy. A. LILRB3*12-Fc binding colocalised with the binding of the mAbs 1E8 (anti-cytokeratin 8) and DA-7 (anti-
cytokeratin 18) in permeablised MCF-7 cells that were previously transduced with a non gene-specific shRNA construct. shRNA constructs 
were used to stably silence the expression of cytokeratin 8 in MCF-7 epithelial cells. Binding of both mAbs and LILRB3*12-Fc were 
greatly reduced in MCF-7 cytokeratin 8 knock down cells (CK8 KD). Bar represents 10μm. B. MCF-7 cells that were previously transduced 
with a non gene-specific shRNA construct were stained with either: i) the 1E8 mAb and Fc negative control construct, or ii) isotype control 
mAb and the LILRB3*12 Fc fusion. Both the isotype and control Fc displayed minimal binding. LILRB3*12-Fc staining did not co-localise 
with phalloidin staining (actin, panel iii) or DM1A mAb (anti-tubulin, panel iv).
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8/18 intermediate filaments during programed cell death, 
a process mediated by caspases, that does not occur in 
necrosis [25].
The concept that transformed, stressed and 
damaged cells expose intracellular molecules that activate 
components of the innate immune system has been 
proposed before [26]. For example, there is evidence 
that myeloid C-type lectin receptors, including DNGR-
1 and DEC205, sense damaged self [27]. It is proposed 
that sterile inflammation may be the consequence of 
recognition of damage-associated molecular patterns, 
or DAMPS [28]. Recognition of DAMPs may lead to 
initiation of T cell responses. Those DAMPs that have 
been characterised comprise intracellular contents that 
have been exposed upon tissue damage, such as F-actin 
[28]. Indeed it has been proposed that exposure of the 
cytoskeleton is an evolutionarily conserved signal of 
damage that excites innate immunity.
Tumour cell necrosis is a common feature of 
malignancy, often occurring within the centre of rapidly 
growing tumours. Our data suggest that the process of 
necrosis leads to exposure of the cytokeratin-associated 
ligand which is then available for recognition by paired 
activating and inhibitory LILRB3 and LILRA6 receptors 
expressed by dendritic and other myelomonocytic cells. 
They are consistent with recognition of cytokeratin ligand 
not being restricted to tumour cells. It is possible that 
macrophage interaction with cytokeratin, through LILR, 
is a signal for recognition of glandular epithelial necrosis, 
which is marked in tumours as they generally contain a 
high proportion of necrotic cells. It is worth noting that 
there are other situations of pronounced necrosis, such as 
liver disease [29]. The balance of signals transmitted by 
inhibitory LILRB3 and activating LILRA6 might therefore 
determine whether an immune response is initiated to the 
dead tumour cell, thereby to influence the wider immune 
response within the tumour microenvironment. In this 
regard it is not surprising that cytokeratin behaves as a 
DAMP. However, our finding that exposed cytokeratin 
may interact both with inhibitory and activating receptors 
is not consistent with simple activation but, rather with 
some degree of regulation of response.
Figure 8: LILRB3 binding is dependent upon expression of cytokeratin 8. A. LILRB3*12-Fc binding of mechanically damaged 
MCF-7 cells following shRNA silencing of cytokeratin 8 expression. The levels of the 1E8 cytokeratin 8 epitope, LILRB3*12-Fc and MHC 
class I (W6/32) were compared in MCF-7 cytokeratin 8 knock down cells (MCF-7 CK8 KD) and MCF-7 cells transduced with a non 
gene-specific shRNA construct. B. Analysis of the mean fluorescence intensity of the 1E8 epitope, the LILRB3 binding ligand and MHC 
class I on MCF-7, MCF-7 CK8 KD and Daudi B cells. The binding of LILRB3*12-Fc and 1E8 was significantly reduced on mechanically 
damaged MCF-7 CK8 KD cells in comparison to MCF-7 cells, whilst both displayed similar expression levels of MHC class I. Bars 
indicate mean values (*p<0.01 using a two-tailed Mann Whitney test; ns= not significant). C. Activation of LILRB3 2B4 reporter cells by 
necrotic MCF-7 cells following shRNA silencing of the expression of cytokeratin 8. Target cells were treated with H2O2 to induce necrosis 
prior to incubation with reporter cells. MCF-7 cells strongly activated LILRB3*12 expressing 2B4 cells whilst the MCF-7 CK8 KD cells 
activated ~4% LILRB3*12 2B4 cells. HEK293T non-epithelial cells were used as a control. The results from 4 replicate experiments are 
shown. For each experiment, assessment of LILRB1 and parental 2B4 reporter cells was performed in duplicate, while assessment of 
LILRB3*12 was performed in quadruplicate. Bars indicate mean values.
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Polymorphic variation in cell surface molecules that 
affect innate immune regulation is generally considered 
to occur in response to immune escape by pathogens. 
An interpretation of our data is that the variation is 
an evolutionary response to pathogens that influence, 
or down-regulate, inflammatory mechanisms to gain 
a selective advantage. Another possibility is that the 
polymorphism has been driven by immune response to cell 
transformation. The finding that polymorphic variants of 
LILRB3 and LILRA6 have very different ligand binding 
characteristics suggests that cells carrying these receptors, 
in individuals possessing high or low ligand binding 
variants of inhibitory LILRB3 or activating LILRA6, will 
be variably activated by epithelial tumours. The scope for 
variability in the response to the cytokeratin - associated 
ligand becomes more complex when combinations of 
high and low binding variants of the activating and 
inhibitory receptors are considered alongside evidence of 
copy number variation in the LILR genes [12, 30]. There 
are other examples of paired activating and inhibitory 
receptors, including the KIR, whose genes are located near 
to the LILR loci in the neighbouring region of chromosome 
19 [11, 31-33].
In common with certain KIR, LILRB3 and LILRA6 
display the hallmark of genes undergoing positive 
selection, with several substitutions displaying statistically 
significant evidence of positive selection pressure 
(Supplementary Table S1). Four polymorphic amino acids 
are located in motifs in the D1, D3 and D4 Ig domains that 
we have shown influence the recognition of tumour cells 
by these LILR receptors (Figure 5).
There are no other data on the physiological 
role of LILRB3 and LILRA6. The differential binding 
characteristics of activating and inhibitory variants to 
necrotic tumour cells could shape local inflammatory 
responses to epithelial tumours. An alternative 
explanation of our findings is that LILRB3/A6 binding 
is a non-physiological artefact due to exposure of 
molecules normally confined to the cytoplasm. This 
remains a possibility, however most tumours contain a 
core of necrotic cells which potentially could interact with 
macrophages. The LILRB3/A6 interaction with these cells 
may be exploitable in an anti-tumour immunotherapy.
MATERIALS AND METHODS
Immunoprecipitation
Immunoprecipitation was performed using protein 
A Dynabeads (Life Technologies) coated with LILR-Fc 
protein. 50μl PBS-T-washed Dynabeads were loaded 
with LILR-Fc following incubation with 50μl of 250μg/
ml freshly made LILR-Fc at 4°C for 1 hour followed by 
two washes with PBS-T. The construction and preparation 
of the LILR-Fc protein is described in the Supplementary 
Material.
Cell lysates (100μl) were precleared by incubation 
at 4°C for 1 hour with 25μl protein A Dynabeads. 
50μl of LILR-Fc loaded Dynabeads were then added 
to the precleared lysate for 1hr at 4°C. Beads were 
washed thrice in cold PBS-T and resuspended with 
LDS loading buffer (30mM Glycine pH2.8, 1x Nupage 
LDS buffer and reducing agent [Life Technologies]). 
Samples were denatured at 70°C for 10 min, before 
loading onto a Nupage 4-12% Bis-Tris SDS PAGE gel 
(Life Technologies) alongside SeeBlue II marker (Life 
Technologies). Gels were run in MOPs buffer (Life 
Technologies) for 45 minutes at 200V. Protein bands were 
visualised following Coomassie Blue staining.
Protein bands in gels were identified by 
fingerprinting of tryptic peptide using an Applied 
Biosystems 4800 Plus MALDI-TOF-TOF Mass 
Spectrometer in CIMR/IMS Proteomics Facility (CIPF) 
of the Cambridge Institute for Medical Research.
Preparation of cytokeratin 8 coupled beads
SpheroTM 5.0-5.9 μm diameter, carboxyl pink 
fluorescent beads (10mg), (Saxon Europe, Kelso UK) 
were conjugated in 2ml of 20μM sodium acetate buffer 
pH5.0 with 0.3mg of protein A (Sigma-Aldrich, St. Louis, 
MO, USA), using 7.65mM N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride as a crosslinking 
agent (Sigma-Aldrich), for 2hrs at RT. Following 2 
washes with PBS pH7.4, 2mg of protein A-conjugated 
beads were incubated for 1hr at room temperature with 
one of the following: 45μg of the anti-human cytokeratin 
8 monoclonal antibody 1E8 (Santa Cruz Biotechnology, 
Dallas, TX, USA), anti-human LILRB3, (clone 222821, 
R&D Systems) or an IgG2a isotype control, (clone 20102, 
R&D Systems). Following 2 washes with PBS pH7.4, 1mg 
of antibody coated beads was incubated at 4°C for 1hr 
with either 500μl MCF-7 or Daudi membrane-enriched 
cell lysates (prepared as described above). Beads were 
washed twice in PBS + 0.02% Tween, and resuspended in 
PBS pH7.4, 5mM EDTA, 2% BSA, 0.02% sodium azide 
and 1x Proteoblock protease inhibitor cocktail (Fermentas) 
and stored at 4°C. Beads were washed with PBS and 
sonicated prior to use.
Flow cytometry
The following mouse monoclonal antibodies 
(mAb) were used in flow cytometry: W6/32, anti-human 
HLA-Class I; 1E8, anti-human cytokeratin 8 (Santa 
Cruz Biotechnology); DA-7, anti-human cytokeratin 18 
(Biolegend); BA-17 anti-human cytokeratin 19, (R&D 
systems and an IgG2a isotype control (Sigma-Aldrich). 
The rabbit monoclonal antibody EPR4628, anti-human 
farnesly diphosphate synthase (FDPS) (GeneTex, Irvine, 
CA, USA), was used alongside negative control rabbit IgG 
(Sigma-Aldrich).
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All primary antibodies were used at a concentration 
of 20μg/ml, while LILR-Fc fusion molecules where used 
at 60μg/ml, unless otherwise stated. Primary staining 
of adherent cells was performed following detachment 
using NECDB unless otherwise stated; staining was also 
performed in situ on 6 well tissue culture plates before 
detachment and subsequent secondary staining. In both 
cases, 105 cells were stained in PBS pH 7.4, 5% FBS for 45 
minutes on ice followed by two washes in PBS pH 7.4, 5% 
FBS. All secondary staining incubations were performed 
on ice for 45 minutes with one of the following, where 
appropriate: 100μl/ml rabbit F(ab’)2 anti-mouse IgG-RPE 
(Serotec, Kidlington, UK); 2μg/ml swine anti-rabbit IgG-
FITC (Dako); or 1.25μg/ml goat F(ab’)2 anti-human IgG 
Fcγ-RPE (Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA) for cells stained with LILR-Fc proteins. 
Cells were washed twice with PBS pH 7.4, 5% FBS 
followed by a final wash with PBS prior to acquisition 
on a FACScan (BD Biosciences, Franklin Lakes, NJ, 
USA) or CyAn ADP (Beckman Coulter) flow cytometers. 
Additionally, cell viability was assessed by addition of 
25μg/ml DAPI di-lactate (Life Technologies) 2 min before 
acquisition. Analysis was performed using Cell Quest (BD 
Biosciences) or Weasel 3.0 (http://www.wehi.edu.au).
Externalization of phosphatidylserine, an 
indicator of apoptosis, was assessed by Annexin V-APC 
staining (BD Bioscience) following the manufacturer’s 
recommended protocol and acquired using a CyAn ADP 
flow cytometer.
Confocal microscopy
MCF-7 cells were seeded on uncoated glass 
coverslips and left overnight to adhere. The following 
cell preparations and staining were performed on ice: 
Cells were fixed with 4% paraformaldehyde in 250mM 
Hepes buffer for 10 mins and permeablised using 0.1% 
Triton X/PBS for 10 min before washing twice with PBS. 
Intracellular primary staining was performed using 20μg/
ml of the mAbs 1E8, DA-7, BA-17, or 1μg/ml of DM1A 
(mouse anti-α-tubulin, Millipore) and 5U/ml of Phalloidin 
Alexa Fluor 647 (Molecular Probes) in conjunction with 
60μg/ml of LILRB3-Fc fusion. Cells were stained in 
PBS/5% FBS for 1 hour followed by two washes with 
PBS/5% FBS and a further 1hr incubation with 2μg/ml goat 
anti-mouse Alexa Fluor 647 (molecular probes) and 1.7μg/
ml goat F(ab’)2 anti-human IgG Alexa Fluor 488 (Jackson 
ImmunoResearch Laboratories), where appropriate. Cells 
were washed twice with PBS/5% FBS, followed by one 
wash with PBS. Finally, coverslips were mounted on glass 
slides using Mowiol 4-88 containing 0.5μg/ml DAPI. 
Cells were viewed using an Axio Observer Z1 confocal 
microscope (Ziess) with a 100x oil-immersion objective 
lens and images acquired using ZEN software (Ziess).
LILR-2B4 reporter assays
The construction of the LILR-2B4 reporter cells 
is described in Supplementary material. Cloned or 
sorted (but polyclonal) 2B4 reporter cells (2x104) were 
co-cultured at a ratio of 1:3 with target cells or 16.7μg of 
antigen-coated beads in 200μl RPMI/10% FBS in 96 well 
U-bottomed cell culture plates (Nalge Nunc, Penfield, NY, 
USA). Adherent target cells were either co-seeded with 
the 2B4 reporter cells or allowed to adhere onto the plates 
prior to washing (to remove dead cells) and the addition 
of reporter cells. Plates were centrifuged for 1 min at 
200g and incubated for 20 hours at 37°C in 5% CO2 air 
atmosphere. To provide a positive control, LILR were 
cross-linked with either 25μl/ml anti-HA mAb (Miltenyi 
Biotec) followed by 25μl/ml rabbit F(ab’)2 anti-mouse 
IgG (Serotec), or 12.5 μg/ml anti-LILRB3 mAb (R&D 
Systems; clone 222821). The percentage of 2B4 reporter 
cells expressing GFP was assessed using a FACScan flow 
cytometer (BD Biosciences). The LILRB3 2B4 reporter 
cell-line expressing allele LILRB3*12 was used in all 
assays unless otherwise stated.
shRNA silencing of cytokeratin 8 expression by 
MCF-7 cells
A replication incompetent lentiviral vector was 
used to stably transduce MCF-7 cells with a short mRNA 
hairpin (shRNA) construct designed to target human 
cytokeratin 8 mRNA. Transduction with an shRNA 
sequence with no target in the human genome was used 
as a negative control. Appropriate hairpin sequences 
were obtained from the RNAi consortium (http://
www.broadinstitute.org/rnai/public/). The cytokeratin 
8 specific hairpin was constructed from the oligomer 
pair CCGGGGATGCAGAACATGAGTATTCC 
TCGAGGAATACTCATGTTCTGCATCCTTT 
TTG and AATTCAAAAAGGATGCAGAACATGAGTA 
TTCCTCGAGGAATACTCATGTTCTGCATCC 
(TRCN0000421337), and the control hairpin from 
CCGGGCTTCAAGTGGGAGCGCGTGACTCGA 
GTCACGCGCTCCCACTTGAAGCTTTTTG and 
AATTCAAAAAGCTTCAAGTGGGAGCGCG 
TGACTCGAGTCACGCGCTCCCACTTGAAGC 
(TRCN0000072208).
Cell treatments
Necrosis was induced in cell lines by the addition 
of 160mM NaN3 or 0.5mM H2O2 into the culture medium. 
1μM staurosporine (STS) was used to induce apoptosis. 
Both treatments were performed for 16hrs. Cells were also 
incubated for 1 hour with H2O to induce osmotic lysis, or 
subjected to mechanical damage by repeated trituration.
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Statistical analysis
LILR-Fc binding and 2B4 reporter responses were 
assessed for statistical significance using a two-tailed 
Mann Whitney test in Graphpad 4 software (San Diego, 
CA, USA).
Protein structural modelling of LILRB3 Ig 
domains
Models for three protein sequences encompassing 
D1 to D2, D2 to D3 and D3 to D4 of LILRB3*12 were 
generated by the structural protein prediction server 
Raptor X [34] using default settings. Raptor X performed 
well in our evaluation of online structural prediction 
servers (data not shown). A four Ig-domain representation 
of LILRB3 was constructed from the D1-D2 and D3-
D4 models generated by Raptor X. Alignment of these 
two regions was achieved using the D2-D3 model as a 
structural template. All models were evaluated in terms of 
energy and stereochemical properties using Qmean6 [35, 
36], Dfire [37] and Procheck (Ramachandran and G-factor 
analysis) [38]. Models were visualised using PyMol.
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